America is the global leader in health care innovation. We lead in medical research and in rapidly developing treatments for emerging health care priorities. That leadership isn’t free. But it isn’t ...

Met primary endpoint of safety and tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse events In comparison to placebo, treatment with REC-994 400 mg showed ...

Recursion Pharmaceuticals (NASDAQ:RXRX) on Tuesday announced topline results from its SYCAMORE Phase 2 trial for its most advanced candidate REC-994 in symptomatic cerebral cavernous malformation (CCM ...

Recursion Pharmaceuticals announced results of a clinical trial for its lead drug candidate Tuesday that, while a success on paper, likely won’t satisfy many investors closely watching the AI drug ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Recursion Pharmaceuticals Inc before investing. In this article, we go over a few ...

Abstract: Random testing represents a simple and tractable way for software assessment. This paper presents the Seed tool that can be used for the uniform random generation of recursive data ...